- Reaction score
- 171
How soon until this stuff is available on the grey market in the US?
Phase 2 for GT20029 (AR degrader) Begins in China
Kintor Pharma just completed the first patient enrollment in China for its proteolysis targeting chimera (PROTAC) compound GT20029. The Phase II clinical trial is a multi-center, randomized, double-blind, placebo-controlled study. It will evaluate the efficacy and safety of androgen receptor degrader GT20029 for treating male pattern baldness in Chinese adults. Kintor plans to enroll a total of 180 male Androgenetic Alopecia patients from 12 centers nationwide.
Kintor Pharmaceutical Starts Phase 3 Trials | Hair Loss Cure 2020
Kintor Pharmaceutical was founded in China. Kintor's pyrilutamide AR antagonist will treat hair loss (androgenic alopecia). Phase 3 trials begin in early 2022.
www.hairlosscure2020.com
Phase 2 for GT20029 (AR degrader) Begins in China
Kintor Pharma just completed the first patient enrollment in China for its proteolysis targeting chimera (PROTAC) compound GT20029. The Phase II clinical trial is a multi-center, randomized, double-blind, placebo-controlled study. It will evaluate the efficacy and safety of androgen receptor degrader GT20029 for treating male pattern baldness in Chinese adults. Kintor plans to enroll a total of 180 male Androgenetic Alopecia patients from 12 centers nationwide.